An Interview With MannKind CEO Michael Castagna
Michael Castagna took over as CEO of MannKind Corporation (NASDAQ: MNKD) on May 25, 2017, after serving for around a year as chief commercial officer. At the time, the biotech had lost more than half of its market cap in less than five months, with a share price near $1.40. Since then, MannKind's market cap has increased by more than 120%. It's been one of the hottest biotech stocks on the market over the past few months.
I had the opportunity to interview Castagna recently about MannKind's past and current challenges, and about what the near term could look like for the company. Our discussion on the company's longer-term prospects will be featured in a forthcoming article. Comments have been edited lightly for clarity, flow, and length.
Image source: MannKind on Twitter.
Source: Fool.com
